Trajectories of progressive pulmonary fibrosis and outcomes in connective tissue disease associated interstitial lung disease (CTD-ILD).
Sarcoidosis vasculitis and diffuse lung diseases · 30.09.2026 · 43 (3) · 18859-18859
DOI: 10.36141/svdld.2026.18859 ↗Kurz gefasst
Fachartikel in der Zeitschrift Sarcoidosis vasculitis and diffuse lung diseases, erschienen am 30.09.2026. Verfasst von Jeewon Lee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic Unive…. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND AND AIM: Progressive pulmonary fibrosis (PPF) can develop in various interstitial lung diseases (ILD), including connective tissue disease-associated ILD (CTD-ILD). This study aimed to examine the longitudinal trajectory and transition of PPF status in patients with CTD-ILD. METHODS: In this single-center study at a tertiary referral hospital, we analyzed patients with CTD-ILD who underwent consecutive chest computed tomography (CT) scans and pulmonary function tests over two-year period. Patients were categorized into four groups based on annual PPF status. RESULTS: Among the 144 patients, the majority (n = 75) maintained a non-PPF status throughout follow-up (Group 1), while 25 patients developed PPF at year 2 (Group 2), 12 showed PPF improvement (Group 3), and 31 had persistent PPF (Group 4). The persistent PPF group showed significantly higher mortality risk (p = 0.007). Based on PPF status at 2 years, annual changes in forced vital capacity (FVC) and diffusing capacity of carbon monoxide (DLCO) were more pronounced in PPF groups than in non-PPF groups (FVC: -3.72 ± 0.52 %/year vs. 2.82 ± 0.41 %/year; DLCO: -4.30 ± 0.75 %/year vs. 3.64 ± 0.60 %/year). Patients treated with immunomodulating agents showed a reduced risk of progression to PPF, although the association was not statistically significant (Group 2, adjusted odds ratio: 0.26, 95% CI: 0.02-4.43, p = 0.351). CONCLUSIONS: Regular pulmonary function monitoring and continuous assessment of PPF progression are essential for patients with CTD-ILD. Disease-directed treatment may reduce the risk of PPF development.
Schlagwörter
Autor:innen und Institutionen
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Zitieren
APA
Lee, J., Kim, A., Kim, K., Nam, J. H., Lee, J. M., & Jo, Y. S. (2026). Trajectories of progressive pulmonary fibrosis and outcomes in connective tissue disease associated interstitial lung disease (CTD-ILD). Sarcoidosis vasculitis and diffuse lung diseases, 43(3), 18859-18859. https://doi.org/10.36141/svdld.2026.18859
Vancouver
Lee J, Kim A, Kim K, Nam JH, Lee JM, Jo YS. Trajectories of progressive pulmonary fibrosis and outcomes in connective tissue disease associated interstitial lung disease (CTD-ILD). Sarcoidosis vasculitis and diffuse lung diseases. 2026;43(3):18859-18859. doi:10.36141/svdld.2026.18859
BibTeX
@article{Lee2026,
author = {Lee, Jeewon and Kim, Ahran and Kim, Kyuhwan and Nam, Jung Hyun and Lee, Jong Min and Jo, Yong Suk},
title = {Trajectories of progressive pulmonary fibrosis and outcomes in connective tissue disease associated interstitial lung disease (CTD-ILD)},
journal = {Sarcoidosis vasculitis and diffuse lung diseases},
year = {2026},
volume = {43},
number = {3},
pages = {18859--18859},
doi = {10.36141/svdld.2026.18859}
}
EUVIMED